


Journal Pre-proof

Peritoneal dialysis-related infections due to nontuberculous *Mycobacteria* in children and adolescents: a critical review of reported cases

John Dotis Antonia Kondou Vasiliki Karava Athina Papadopoulou
Nikoleta Printza



PII: S0211-6995(25)00116-X

DOI: <https://doi.org/doi:10.1016/j.nefro.2025.501406>

Reference: NEFRO 501406

To appear in: NEFROLOGÍA

Received Date: 24 April 2025

Accepted Date: 19 August 2025

Please cite this article as: Dotis J, Kondou A, Karava V, Papadopoulou A, Printza N, Peritoneal dialysis-related infections due to nontuberculous *Mycobacteria* in children and adolescents: a critical review of reported cases (2025), doi: <https://doi.org/10.1016/j.nefro.2025.501406>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología.

Infecciones relacionadas con la diálisis peritoneal por micobacterias no tuberculosas en niños y adolescentes: una revisión crítica de casos reportados

Peritoneal dialysis-related infections due to nontuberculous *Mycobacteria* in children and adolescents: a critical review of reported cases

John Dotis^{1*}, Antonia Kondou², Vasiliki Karava³, Athina Papadopoulou², Nikoleta Printza²

¹Third Department of Pediatrics, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece

²First Department of Pediatrics, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece

³First Department of Pediatrics, National and Kapodistrian University of Athens, Agia Sofia Children's Hospital, Athens, Greece

*Corresponding author:

John Dotis

Third Department of Pediatrics, Hippokratio General Hospital of Thessaloniki, 49th Konstantinoupoleos Street, 54642 Thessaloniki, Greece

Email: yandot@auth.gr

Resumen

Las infecciones relacionadas con la diálisis peritoneal (DP) debidas a Micobacterias no tuberculosas (MNT) son raras en niños y adolescentes, pero parecen ser cada vez

más reconocidas. Con el fin de comprender mejor el perfil clínico, las características, el manejo y los desenlaces de estas infecciones, realizamos una revisión sistemática de los casos pediátricos reportados en la literatura. Se identificaron 25 episodios en 23 pacientes menores de 18 años, extraídos de 19 estudios. La edad media fue de 7,35 años, con un ligero predominio masculino. La condición subyacente más común que condujo a enfermedad renal terminal e inicio de DP fue la presencia de anomalías congénitas del riñón y de las vías urinarias, particularmente riñones hipoplásicos o displásicos. Las manifestaciones clínicas fueron inespecíficas, incluyendo con frecuencia fiebre, dolor abdominal y líquido efluente turbio. Entre los casos reportados, el 52% presentó peritonitis, el 36% infección del sitio de salida y el 12% ambas. *Mycobacterium abscessus* y *Mycobacterium fortuitum* surgieron como las especies más prevalentes, representando proporciones similares entre los aislamientos recuperados. Cabe destacar que *Mycobacterium chelonae* fue la especie más frecuentemente aislada entre los lactantes. El diagnóstico fue frecuentemente tardío y el tratamiento requirió regímenes antibióticos prolongados. En casi todos los casos se realizó la retirada del catéter, y la mayoría de los pacientes fue transferida temporalmente a hemodiálisis. La tasa de mortalidad fue baja, aproximándose al 4%. Estos hallazgos subrayan la necesidad de mantener una alta sospecha clínica, realizar un diagnóstico temprano y aplicar un manejo agresivo para mejorar los desenlaces en pacientes pediátricos con infecciones relacionadas con DP por MNT.

Palabras clave: Micobacterias no tuberculosas, diálisis peritoneal, peritonitis, infección del sitio de salida

Abstract

Peritoneal dialysis (PD)–related infections due to nontuberculous *Mycobacteria* (NTM) are rare in children and adolescents but appear to be increasingly recognized. To better understand the clinical profile, characteristics, management and outcomes of these infections, we conducted a systematic review of pediatric cases reported in the literature. We identified 25 episodes in 23 patients under the age of 18, drawn from 19 studies. The mean age was 7.35 years with a slight male predominance. The most common underlying condition leading to end stage renal disease and initiation of PD, was congenital anomalies of the kidney and urinary tract, particularly hypoplastic or dysplastic kidneys. Clinical manifestations were non-specific, often including fever, abdominal pain and cloudy effluent. Among the reported cases 52% presented with peritonitis, 36% with exit site infection and 12% had both. *Mycobacterium abscessus* and *Mycobacterium fortuitum* emerged as the most prevalent species, each accounting for a comparable proportion of the recovered isolates. Notably, *Mycobacterium chelonae* was the most frequent isolated specie among infants. Diagnosis was frequently delayed and treatment required prolonged antibiotic regimens. Catheter removal was performed in almost all cases, while most patients were temporarily switched to hemodialysis. Mortality rate was low approaching 4%. These findings underscore the need for heightened clinical suspicion, early diagnosis and aggressive management to improve outcomes in pediatric patients with PD-related infections due to NTM.

Keywords: nontuberculous *Mycobacteria*, peritoneal dialysis, peritonitis, exit site infection

Introduction

Peritoneal dialysis (PD)–related infections due to nontuberculous *Mycobacteria* (NTM) constitute a rare complication of PD, which is even rarer in children and adolescent, accounts less than 1% of peritonitis cases.^{1,2} Noteworthy is the fact that the incidence and prevalence rate of PD–related infections caused by NTM seems to have been increasing.³ The diagnostic problem for these specific infections based on the fact that can be misidentified as other pathogens including diphtheroids or *Corynebacterium* species, leading to delayed diagnosis.¹ When suspected, there is a need for further evaluation requiring acid-fast bacilli stain and culture on specific media or automated system analysis even whole-genome sequencing (WGS). Species including *Mycobacterium fortuitum*, followed by *Mycobacterium abscessus*, *Mycobacterium chelonae* and *Mycobacterium avium* are the most common NTM isolates known to cause PD-related infections, both PD-related peritonitis or PD catheter-related infection such as exit-site infection (ESI) and tunnel infection.^{1,2,4} Problematic is also the appropriate management and treatment of these infections, especially with respect to the relocation of the exit site and catheter removal, which is remain unclear. However, in general two agents with in vitro activity against the clinical isolate of NTM infection for a minimum duration of 4 months, seems to be the appropriated treatment based on the ISPD recommendations.²

Data about the incidence, diagnostic methods, management, treatment and prognosis of NTM infections in children undergoing PD are scarce. It is noteworthy that there are no retrospective studies that include the full number of pediatric cases found in the literature, but usually include a smaller number of cases. Based on that, we conducted a thorough systematic review of literature focusing in PD-related infections caused by NTM in children and adolescents less than 18 years-old, because

there are very limited data available. Accordingly, this literature review aimed to investigate in depth these rare and difficult to cure infections.

Methods

General Information and Literature Search Strategy

This review conforms to the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) statement.^{5,6} (PROSPERO 2024 CRD42024611361; available from https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024611361; accessed on 18 November 2024).

Eligibility Criteria

Case reports of PD-related infections, comprising peritonitis and/or exit site infections, due to NTM in children and adolescents, are incorporated in this review. The diagnosis of peritonitis was based on criteria covering clinical manifestations such as abdominal pain, nausea and fever combined with a cloudy peritoneal effluent count of 100 WBC/ μ L or greater, composing of at least 50% PMN cells and a positive culture of peritoneal effluent. With two at least of the above, diagnosis of peritonitis is established.² An exit-site infection (ESI) was defined as the presence of purulent drainage, with or without erythema of the skin at the catheter-skin interface. In addition, tunnel infection may present as erythema, edema, or tenderness over the subcutaneous pathway but is commonly clinically occult.^{2,4} Tunnel infection usually occurs in the presence of an ESI. Both peritonitis and ESIs were defined as a case presenting with a positive culture for NTM from peritoneal fluid or pus or tissue culture from the exit site. The identification of NTM was made by acid-fast bacilli stain and established either by conventional tests or by an automated system [matrix-

assisted laser-desorption ionization-time of flight mass spectrometry (MALDI-TOF)] or by dialysis effluent polymerase chain reaction (PCR) or by WGS.

Information Sources and Search Strategy

We searched the literature for PD-related infections caused by NTM in children and adolescents (0 - \leq 18 years-old). Articles were obtained from two databases: PubMed (US National Library of Medicine National Institutes of Health, www.ncbi.nlm.nih.gov/pubmed, accessed on 1 February 2025) and Google Scholar (Google, www.scholar.google.com, accessed on 1 February 2025). Databases were searched using the keywords “nontuberculous *Mycobacteria*” and “peritonitis” and/or “exit-site infection” and “peritoneal dialysis” and “children/adolescents” in any available language. For the translation of text, we used the Google online translation tool (Google, <https://translate.google.gr>, accessed on 28 February 2025).

Study Selection

All potentially relevant articles published through 1 February 2025 were screened in two stages for eligibility by selected authors based on their previous experience in such reviews. In the first stage of assessment, the titles and abstracts of potentially relevant articles were screened independently by three authors (JD, AK, AP). The reference list for each article was examined to verify that all published cases had been collected. For those abstracts that met the inclusion criteria, the full text was retrieved and independently reviewed by two authors in the second stage of assessment (VK, NP). Disagreements and technical uncertainties were discussed and resolved by all authors (JD, AK, VK, AP, NP).

Data Extraction

The primary citations obtained during the database survey were recorded in a text file according to their topics and abstracts. None of the case reports found were

excluded from enrolment in the analysis due to the quality or inadequacy of data reported, although in some reports all data were not available. Variables included in the database were the year of publication, origin, demographic information (gender and age), underlying disease leading to end stage renal disease (ESRD), previous peritonitis episodes, symptoms, temperature levels and laboratory findings during admission, predisposing factors, diagnosis method and NTM sensitivity patterns. In addition, data on treatment choice, duration and route of treatment, catheter removal procedure and outcome were also recorded.

Ethics Statement

Due to the retrospective, literature review nature of the study, the Ethics Committee of our Hospital, determined that patients' consent was not required.

Statistical Analysis

All articles found were systematically reviewed, and a master database was constructed. Microsoft Excel software (XP Professional) version 5.2.3790.1830 (Redmond, WA, USA) was used to develop this database of categorical and continuous variables. The statistical program Graphpad InStat 3.10 (Graphpad Inc., San Diego, CA, USA) was used. A two-sided p-value of <0.05 indicated statistical significance.

Results

The search strategy yielded 910 scientific articles which were reviewed. After selection using PRISMA methodology, a total of 25 cases of PD-related infections caused by NTM in children and adolescents were identified in 19 articles and presented in Fig. 1.⁷⁻²⁵ The total number of cases involved 23 patients. The first report of NTM peritonitis in a PD child appeared in 1983.⁷ Their mean (\pm SE) age was 7.35 ± 5.63 years (range, 3 months – 18 years), while, the most cases occurred in males

(15/25, 60%) (Table 1). Twelve (48%) of the cases were reported from Japan, followed by 7 (28%) which were from USA and 1 case each was from Qatar, Singapore, Spain, India, Canada and Saudi Arabia, respectively.

Diseases leading to ESRD were described in 23 of the 25 reviewed cases, in which was found that was secondary to congenital anomalies of the kidney and urinary tract (CAKUT) in 9 cases (39.1%), especially hypo- and or dysplastic kidney in 7 out of them. Twelve (52%) of 25 reported cases experienced peritonitis, 9 (36%) cases experienced ESI and the rest 3 (12%) cases suffered by both peritonitis/ESI.

Mean of vintage on PD in 19 cases with reported data was 16.89 months (range, 1 month – 72 months), while in 11/19 (57.9%) vintage duration was equal or less than 12 months. Continuous ambulatory peritoneal dialysis (CAPD) was the commonest PD method used in 52% of cases. The clinical profile of PD-associated with NTM infections was non-specific, specifically, fever (52%), abdominal pain (44%), cloudy effluent (40%) were the most common manifestations. However, in 12 cases with PD-associated with NTM infections including ESI, either alone or combined with peritonitis, 91.7% of cases showed inflammatory skin lesions or were purulent.

Microbiological findings and management of 25 cases of PD-related infections caused by NTM presented in Table 2. The most prevalent organisms responsible for PD-associated with NTM infections was *M. abscessus* and *M. fortuitum* (28%), each, followed by *M. chelonae* (24%) and *Mycobacterium avium* (16%) (Table 3). *Mycobacterium chelonae* PD-associated infections occurred in children with a mean age of 12 months (range, 3 months – 26 months), constituting the NTM pathogen which affects the youngest age group among patients reviewed. Only cases with confirmed peritoneal effluent or exit site tissue culture were included in this review.

The pathogens were further verified by molecular methods (PCR) in 3 of the 25 cases, 2 cases by MALDI-TOF analysis and 1 case by WGS method.

In 23 (95.8%) of 24 cases with reported data, the PD catheter was removed and patients were given a novel PD catheter (25%) continuing PD methodology or most commonly switched to hemodialysis (75%). In 3 cases, a transition from PD to hemodialysis was necessitated and this was subsequently followed by successful renal transplantation, highlighting a favorable clinical course despite the complexity of their prior management.

All patient initially received empirical antibacterial treatment, which was subsequently modified in the majority of cases to ensure adequate coverage against NTM, following mycobacterial identification and susceptibility testing. The treatment duration ranged from 1 month to 12 months with a mean and median of the treatment, in cases with reported data, being 5.6 and 6 months, respectively. The anti-NTM regimen was selected according to specific isolates and/or in vitro anti-mycobacterial susceptibility. The most commonly used agents for the treatment of PD-associated with NTM infections included macrolides, aminoglycosides, fluoroquinolones, tetracyclines, carbapenems, oxazolidinones, rifampin, ethambutol and rifabutin. The outcome was favorable in all cases, with the sole exception of one patient who unfortunately died due to the infection. Notably, this particular case represented the first ever published report of PD-associated with NTM infections more than four decades ago.⁷

Discussion

Our systematic review revealed 25 pediatric cases of PD-associated with NTM infections published to date, most of them reported as isolated case reports. *M.*

abscessus and *M. fortuitum* were the predominant species in this cohort mirrors trends in both adult and pediatric populations.^{26,27} However, there appears to be a shift in recent years toward broader recognition of species such as *M. chelonae* and *M. avium*, partly due to improved identification techniques including MALDI-TOF and PCR.⁴ Diagnostic delays remain a major issue, with initial cultures often misidentified as diphtheroids or contaminated samples.¹ Furthermore, the lack of clinical suspicion, especially in patients presenting with mild or atypical symptoms, such as localized exit-site inflammation without systemic signs, contributes to diagnostic inertia.

Differentiating PD-related infections caused by NTM from those due to conventional bacterial pathogens remains a significant clinical challenge but is essential for timely diagnosis and effective management. While both entities can present with non-specific symptoms such as fever, abdominal pain or cloudy effluent, a key distinguishing feature of NTM infections is their poor or absent response to empirical broad-spectrum antibiotics, which should raise early clinical suspicion in refractory cases.^{1,2} Diagnostic delays are common, as standard microbiological methods may fail to detect NTM or misidentify them as contaminants, underscoring the need for acid-fast staining and specialized culture techniques, or advanced modalities such as MALDI-TOF, PCR or WGS.^{4,27} Although epidemiological differences in age or PD vintage between NTM and common bacterial infections are not consistently pronounced, our review shows that NTM infections more frequently require PD catheter removal and a temporary shift to hemodialysis, suggesting a more complex clinical course.^{3,25,26} Taken together, these factors emphasize the importance of maintaining a high index of suspicion for NTM, particularly in cases unresponsive to standard treatment protocols, to ensure prompt diagnostic confirmation and implementation of appropriate therapy.

The reviewed pediatric cases revealed substantial variation in clinical presentation and therapeutic approaches. Peritonitis was the most frequent manifestation, although ESI were also common. In our study, the mean duration on PD prior to the onset of NTM infection was approximately 17 months, with a substantial proportion of cases occurring within the first year following the initiation of PD as renal replacement therapy. This suggests a potential role of early technique training, catheter care protocols and environmental exposure in disease pathogenesis.^{2,26} Fever, abdominal pain and cloudy effluent were common but not universal findings. Interestingly, most cases involving ESI were accompanied by skin lesions or purulent discharge, highlighting the importance of local signs in early suspicion of NTM.²⁶

From a microbiological standpoint, culture positivity from peritoneal fluid or exit-site samples remains the cornerstone of diagnosis. However, newer techniques such as MALDI-TOF and PCR provide more rapid and accurate identification, especially in slow-growing or atypical isolates like mycobacteria.⁴ The use of WGS remains limited in routine clinical practice, but may become more accessible in tertiary centers in the near future and it will probably be the method of choice for the detection of these pathogens.

Treatment strategies varied considerably, both in terms of antibiotic selection and therapy duration. According to the ISPD guidelines, at least two antimycobacterial agents with in vitro activity against the isolate should be used, ideally for a minimum of four months.² However, in practice as was found in our study, therapy duration ranged from a few weeks to several months and a wide variety of drug combinations, which were often empirical due to limited susceptibility data, were administered. In general, macrolides, fluoroquinolones, amikacin and linezolid

were the most frequently used agents in literature, either alone or in combination, which are in accordance with our findings.^{25,26}

Catheter removal was performed in the majority of cases, often after failure of initial empirical therapy. Early removal may be advisable, especially in tunnel or ESI, to prevent progression to peritonitis or systemic dissemination. However, the optimal timing of catheter removal and subsequent reinsertion remains poorly defined in the pediatric setting and should be individualized based on clinical response and microbial eradication. While catheter salvage is possible in select cases of localized ESI, relapsing infections and persistent inflammation frequently necessitate catheter replacement or a temporary switch to hemodialysis.^{1,4,27}

The long-term prognosis of pediatric patients with NTM-related PD infections is generally favorable when appropriately treated, although some cases are associated with PD method failure and transition to hemodialysis. There are no clear recommendations on the optimal timing for reinitiating PD after catheter removal due to NTM infection and decisions are often individualized. Given the chronic nature of the underlying kidney disease in most of these children, preserving peritoneal membrane function and minimizing disruptions in dialysis modality are critical considerations.^{1,26}

This study is limited by the small sample size, reflecting the rarity of PD-related infections due to NTM. The retrospective nature of case reports and the heterogeneity of data present significant challenges. This includes the infrequent reporting of specific peritoneal dialysis solution types in the included case reports, which prevented a comprehensive analysis of their potential influence on infection risk. Furthermore, incomplete reporting on treatment regimens, duration, and outcomes in some cases limits our ability to draw firm conclusions about optimal management

strategies. Another emerging issue is the potential underreporting of cases. Given the difficulty in diagnosis and frequent misidentification, the true incidence of NTM-related PD infections may be underestimated, especially in resource-limited settings. Moreover, the inclusion of cases only with confirmed positive cultures may lead to selection bias in existing literature. However, despite these limitations, our study contributes valuable insights into an underreported condition and supports the need for heightened clinical suspicion and tailored microbiological evaluation in pediatric PD patients.

Notwithstanding the slowly growing number of case reports, there remains a lack of high-quality evidence and consensus on optimal management. The heterogeneity in treatment approaches highlights the need for standardized treatment protocols based on susceptibility data and pediatric pharmacokinetics. Future research should aim to establish prospective registries and multicenter collaborations to gather more robust data on incidence, outcomes and antimicrobial susceptibility. Until then, clinical suspicion, early diagnosis, aggressive therapy with appropriate agents and timely catheter management remain the cornerstones of successful outcomes.

Key concepts

1. PD-related infections due to NTM in children and adolescents are rare but clinically significant, requiring heightened diagnostic suspicion and vigilance.
2. The predominant pathogens were *M. abscessus*, *M. fortuitum* and *M. chelonae*, often associated with rapid disease progression.
3. Peritonitis and ESIs due to NTM presented with non-specific symptoms.
4. Catheter removal was needed in the majority of cases with most of patients switched to hemodialysis, while a few resumed PD.

5. Treatment required prolonged, species-specific antibiotic regimens, with outcomes generally be favorable.

Conflict of interests

The authors declare that they have no potential conflict of interest related to the contents of this article.

Journal Pre-proof

References

1. Washida N, Itoh H. The role of non-tuberculous mycobacteria in peritoneal dialysis-related infections: a literature review. *Contrib Nephrol* 2018; 196: 155–61. Available from: <https://doi.org/10.1159/000485716>
2. Li PK, Chow KM, Cho Y, Fan S, Figueiredo AE, Harris T, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. *Perit Dial Int* 2022, 42(2): 110–53. Available from: <https://doi.org/10.1177/08968608221080586>
3. Bnaya A, Wiener-Well Y, Soetendorp H, Einbinder Y, Paitan Y, Kunin M, et al. Nontuberculous mycobacteria infections of peritoneal dialysis patients: a multicenter study. *Perit Dial Int* 2021; 41(3): 284–91. Available from: <https://doi.org/10.1177/0896860820923461>
4. Chow KM, Li PKT, Cho Y, Abu-Alfa A, Bavanandan S, Brown EA, et al. ISPD Catheter-related Infection Recommendations: 2023 Update. *Perit Dial Int* 2023; 43(3): 201–19. Available from: <https://doi.org/10.1177/08968608231172740>
5. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6(7): e1000097. Available from: <https://doi.org/10.1371/journal.pmed.1000097>
6. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. *JAMA* 2015; 313(16): 1657–65. Available from: <https://doi.org/10.1001/jama.2015.3656>
7. Pulliam JP, Vernon DD, Alexander SR, Hartstein AI, Golper TA. Nontuberculous mycobacterial peritonitis associated with continuous

- ambulatory peritoneal dialysis. *Am J Kidney Dis* 1983; 2(6): 610–4. Available from: [https://doi.org/10.1016/S0272-6386\(83\)80040-7](https://doi.org/10.1016/S0272-6386(83)80040-7)
8. LaRocco MT, Mortensen JE, Robinson A. *Mycobacterium fortuitum* peritonitis in a patient undergoing chronic peritoneal dialysis. *Diagn Microbiol Infect Dis* 1986; 4(2): 161–4. Available from: [https://doi.org/10.1016/0732-8893\(86\)90151-3](https://doi.org/10.1016/0732-8893(86)90151-3)
 9. Dunmire RB 3rd, Breyer JA. Nontuberculous mycobacterial peritonitis during continuous ambulatory peritoneal dialysis: case report and review of diagnostic and therapeutic strategies. *Am J Kidney Dis* 1991; 18(1): 126–30. Available from: [https://doi.org/10.1016/S0272-6386\(12\)80303-9](https://doi.org/10.1016/S0272-6386(12)80303-9)
 10. Hakim A, Hisam N, Reuman PD. Environmental mycobacterial peritonitis complicating peritoneal dialysis: three cases and review. *Clin Infect Dis* 1993; 16(3): 426–31. Available from: <https://doi.org/10.1093/clind/16.3.426>
 11. Ferrara E, Lemire J, Grimm PC, Reznik VM, Mendoza SA, Leake JA, et al. Mycobacterial peritonitis in pediatric peritoneal dialysis patients. *Pediatr Nephrol* 2004; 19(1): 114–7. Available from: <https://doi.org/10.1007/s00467-003-1348-1>
 12. Ellis EN, Schutze GE, Wheeler JG. Nontuberculous mycobacterial exit-site infection and abscess in a peritoneal dialysis patient. A case report and review of the literature. *Pediatr Nephrol* 2005; 20(7): 1016–8. Available from: <https://doi.org/10.1007/s00467-005-1870-4>
 13. Sangwan J, Lathwal S, Kumar S, Juyal D. *Mycobacterium fortuitum* Peritonitis in a Patient on Continuous Ambulatory Peritoneal Dialysis (CAPD): A Case Report. *J Clin Diagn Res* 2013; 7(12): 2950–1. Available from: <https://doi.org/10.7860/JCDR/2013/6771.3803>

14. Miyashita E, Yoshida H, Mori D, Nakagawa N, Miyamura T, Ohta H, et al. *Mycobacterium avium* complex-associated peritonitis with CAPD after unrelated bone marrow transplantation. *Pediatr Int* 2014; 56(6): e96–e98. Available from: <https://doi.org/10.1111/ped.12463>
15. Martínez López AB, Álvarez Blanco O, Ruíz Serrano MJ, Morales San-José MD, Luque de Pablos A. *Mycobacterium fortuitum* as a cause of peritoneal dialysis catheter port infection. A clinical case and a review of the literature. *Nefrologia* 2015; 35(6): 584–6. Available from: <https://doi.org/10.1016/j.nefro.2015.09.010>
16. Yamada T, Ushijima K, Uemura O. A hospital-acquired outbreak of catheter-related nontuberculous mycobacterial infection in children on peritoneal dialysis. *CEN Case Rep* 2015; 4(1): 43–7. Available from: <https://doi.org/10.1007/s13730-014-0137-y>
17. Imam O, Al-Zubaidi K, Janahi M, Imam A, Leghrouz B, Dobson S, et al. Peritoneal Dialysis-Associated Peritonitis Caused by *Mycobacterium abscessus* in Children-A Case Report. *Open Forum Infect Di.* 2020; 8(1): ofaa579. Available from: <https://doi.org/10.1093/ofid/ofaa579>
18. Pinapala A, Koh LJ, Ng KH, Tambyah PA, Yap HK. Clofazimine in *Mycobacterium abscessus* peritonitis: A pediatric case report. *Perit Dial Int* 2021; 41(1): 104–9. Available from: <https://doi.org/10.1177/0896860820909702>
19. Yokota S, Nishi K, Ishiwa S, Uda K, Shoji K, Kamei K. *Mycobacterium avium* complex peritonitis in a pediatric patient on peritoneal dialysis: A case report. *Medicine (Baltimore)* 2021; 100(24): e26321. Available from: <https://doi.org/10.1097/MD.00000000000026321>

20. Haubrich K, Mammen C, Sekirov I, Mitchell H. *Mycobacterium fortuitum* peritoneal dialysis-related peritonitis in a child: A case report and review of the literature. *J Assoc Med Microbiol Infect Dis Can* 2022; 7(2): 125–30. Available from: <https://doi.org/10.3138/jammi-2021-0029>
21. Nakano S, Yamamura-Miyazaki N, Michigami T, Yazawa K, Yanagihara I, Yamamoto K. A case of a preschool child with a successful kidney transplant following the long-term administration of antibiotics to treat peritoneal dialysis-related ESI/peritonitis by *Mycobacterium abscessus*. *CEN Case Rep* 2022; 11(4): 408–11. Available from: <https://doi.org/10.1007/s13730-022-00689-z>
22. Khin E, Rodriguez R, Walker SK, Handal G. Peritoneal Dialysis Catheter-Associated Peritonitis Caused by *Mycobacterium abscessus*: A True Infection? *Cureus* 2024; 16(9): e68721. Available from: <https://doi.org/10.7759/cureus.68721>
23. Sakaguchi T, Tamura H, Furuie K, Kuraoka S, Nakazato H. *Mycobacterium fortuitum* Peritoneal Dialysis-Related Peritonitis in a Child: A Case Report. *Biomed Hub* 2024; 9(1): 128–33. Available from: <https://doi.org/10.1159/000541001>
24. Takata K, Omae T, Hamano Y, Ishikawa T, Nogami K. Peritoneal dialysis associated infection caused by *Mycobacterium abscessus* in a pediatric patient on continuous peritoneal dialysis without switching to hemodialysis. *CEN Case Rep* 2024; 13(6): 463–7. Available from: <https://doi.org/10.1007/s13730-024-00875-1>
25. Abukhalid N, Alzahrani, N Alsager K, Alsowailmi B, Albawardi A. Analysis of nontuberculous mycobacterial infections in Saudi children from a tertiary care

hospital perspective. *SSRN* 2025. Available from:

<http://dx.doi.org/10.2139/ssrn.5085100>

26. Song Y, Wu J, Yan H, Chen J. Peritoneal dialysis-associated nontuberculous mycobacterium peritonitis: a systematic review of reported cases. *Nephrol Dial Transplant* 2012; 27(4): 1639–44. Available from: <https://doi.org/10.1093/ndt/gfr504>
27. Johansen MD, Pasipanodya JG, Subbian S, Venketaraman V. Editorial: Recent advancements in mycobacterial diseases research. *Front Microbiol* 2024; 15: 1504449. Available from: <https://doi.org/10.3389/fmicb.2024.1504449>

FIGURE 1. PRISMA flow diagram of literature search, eligibility and inclusion process




Table 1. Cases of peritoneal dialysis-related infections due to nontuberculous *Mycobacteria* (sorting from older to newer)

No	Publication Year, Language, Reference	Country	Age (y)	Gender	Type of infection	Vintage on PD (Months), (Etiology)	PD Method	Previous Peritonitis
1	1983, English, ⁷	USA	16	M	Peritonitis	NA (FSGS)	CAPD	Multiple episodes (previous bacterial peritonitis 5m before)
2	1986, English, ⁸	USA	15	M	Peritonitis	24 (NA)	PD	NA
3	1991, English, ⁹	USA	16	M	Peritonitis	37 (SLE)	CAPD	NA
4	1993, English, ¹⁰	USA	10	M	Peritonitis	NA (prune-belly syndrome)	PD	NA
5	2004, English, ¹¹	USA	18	F	Peritonitis	72 (SLE)	PD	NA
6	2005, English, ¹²	USA	14	F	ESI	NA (SLE)	CCPD	1 episode (previous bacterial peritonitis 6m before)
7	2013, English, ¹³	India	9	F	Peritonitis	1 (chronic glomerulonephritis)	CAPD	No
8	2014, English, ¹⁴	Japan	13	F	Peritonitis	5 (long-term nephrotoxic drugs due to unrelated BMT)	CAPD	No
9	2015, Spanish, ¹⁵	Spain	4	M	ESI	4 (NA)	CAPD	No
10	2015, English, ¹⁶	Japan	25m	F	ESI	12 (complicated urinary tract malformations)	CAPD	No
11	2015, English, ¹⁶	Japan	11m	F	ESI	8 (bilateral hypo-dysplastic kidney)	CAPD	No
12*	2015, English, ¹⁶	Japan	26m	F	ESI	23 (bilateral hypo-dysplastic kidney)	CAPD	1 episode (previous ESI- <i>M. chelonae</i> 15 m before)
13	2015, English, ¹⁶	Japan	3m	M	ESI	2 (angiotensin receptor blocker fetopathy)	CAPD	No
14**	2015, English, ¹⁶	Japan	5m	M	Peritonitis	4 (angiotensin receptor blocker fetopathy)	CAPD	1 episode (previous ESI- <i>M. chelonae</i> 2 m before)
15	2015, English, ¹⁶	Japan	23m	M	ESI	22 (diffuse mesangial	CAPD	1 episode (previous

						sclerosis)		bacterial ESI 1 m before)
16	2015, English, ¹⁶	Japan	4m	F	ESI	3 (right multicystic dysplastic and left hypo-dysplastic kidneys)	CAPD	1 episode (previous bacterial ESI 1 m before)
17	2020, English, ¹⁷	Qatar	9	M	Peritonitis	NA (bilateral multicystic dysplastic kidneys)	APD	recurrent ESIs episodes (previous bacterial ESI 8 m before)
18	2021, English, ¹⁸	Singapore	6	F	Peritonitis/ESI	36 (bilateral dysplastic kidneys)	APD	2 ESIs episodes (previous bacterial ESI 1 m before)
19	2021, English, ¹⁹	Japan	4	M	Peritonitis	NA (bilateral hypoplastic kidneys)	CAPD	1 episode (previous bacterial peritonitis 2w before)
20	2022, English, ²⁰	Canada	9	M	Peritonitis	5 (RT as a result of allograft failure from T-cell-mediated rejection and BK virus nephropathy)	PD	1 episode (previous bacterial peritonitis 1w before)
21	2022, English, ²¹	Japan	32m	M	Peritonitis/ESI	24 (bilateral hypodysplastic kidneys)	APD	5 episodes (previous bacterial peritonitis 2m before)
22	2024, English, ²²	USA	9	M	Peritonitis	10 (reflux nephropathy)	APD	1 episode (previous bacterial peritonitis 4m before)
23	2024, English, ²³	Japan	3	M	Peritonitis/ESI	17 (FSGS)	PD	No
24	2024, English, ²⁴	Japan	10	M	ESI	12 (juvenile nephronophthisis)	CCPD	No
25	2025, English, ²⁵	Saudi Arabia	8	F	Peritonitis	NA (Cystic nephropathy/Obstructive uropathy)	PD	NA

NTM, nontuberculous *Mycobacteria*; PD, peritoneal dialysis; NA, not available; CAPD, continuous ambulatory peritoneal dialysis; SLE, systemic lupus erythematosus; CCPD, continuous cycling peritoneal dialysis; BMT, bone marrow

transplantation; ESI, exit site infection; APD, ambulatory peritoneal dialysis; RT, renal transplantation; FSGS, focal segmental glomerulosclerosis

*Patient 11 and 12 are the same at different age

**Patient 13 and 14 are the same at different age

Table 2. Microbiological findings and management of 24 cases of nontuberculous *Mycobacteria* peritoneal dialysis-related infections

No ^(ref)	NTM isolated	Isolation method	Catheter removal	Hemodialysis switch	Treatment (duration)	Outcome
1 ⁷	<i>M. avium</i>	Culture of PD effluent	Yes	Yes (40th hospital day switch to HD)	ip ampicillin => ip cefoxitin, ip tobramycin => pos isoniazid, pos rifampin, ip amikacin => ip amikacin, iv amikacin	Died (79th hospital day)
2 ⁸	<i>M. fortuitum</i>	Culture of PD effluent	NA	NA	ip cephalothin => iv amikacin, iv cefoxitin=> iv amikacin, pos sulfamethoxazole => surgical drainage of the abscesses	Recovered
3 ⁹	<i>M. fortuitum</i>	Culture of PD effluent	Yes	Yes	ip ceftazolin => ip vancomycin, ip tobramycin, ip amphotericin B => iv vancomycin, iv tobramycin, iv amphotericin B, iv amikacin, iv cefoxitin => pos ciprofloxacin, pos sulfamethoxazole	Recovered
4 ¹⁰	Group II Scotochromogenic M.	Culture of PD effluent	Yes	Yes	ip tobramycin, ip cephalothin => iv amikacin, pos rifampin (1m)	Recovered
5 ¹¹	<i>M. avium</i>	Culture of PD effluent	Yes	Yes	pos azithromycin, pos ethambutol, pos rifabutin	Recovered
6 ¹²	<i>M. abscessus</i>	Culture of ES drainage + PCR	Yes	Yes (19th hospital day switch to HD for 2 months, the PD catheter was replaced and CAPD was resumed)	ip ceftazidime, ip ceftazolin => ip vancomycin, ip ceftazidime => ip amikacin, pos doxycycline, pos rifampin – Extensive surgical debridement of the area and mesh closure of the ventral abdominal wall defect	Recovered
7 ¹³	<i>M. fortuitum</i>	Culture of PD effluent	No	No	ip ciprofloxacin = > pos ciprofloxacin, pos clarithromycin (2m)	Recovered
8 ¹⁴	<i>M. avium</i>	Culture of PD effluent + PCR	Yes	Yes	pos clarithromycin, pos ethambutol, pos levofloxacin	Recovered
9 ¹⁵	<i>M. fortuitum</i>	Culture of ES drainage	Yes	No	ip ciprofloxacin, ip amikacin (12m)	Recovered
10 ¹⁶	<i>M. fortuitum</i>	Culture of ES drainage	Yes	No	iv vancomycin, pos minocycline	Recovered
11 ¹⁶	<i>M. chelonae</i>	Culture of ES drainage	Yes	No	iv vancomycin => iv imipenem/cilastatin, iv minocycline	Recovered

12* ¹⁶	<i>M. chelonae</i>	Culture of ES drainage	Yes	Yes (switch to HD for 2 months, the PD catheter was replaced and CAPD was resumed)	iv vancomycin, iv piperacillin sodium, + pos rifampin => iv clarithromycin, iv levofloxacin	Recovered
13 ¹⁶	<i>M. chelonae</i>	Culture of ES drainage	Yes	No	iv vancomycin, iv teicoplanin => iv amikacin, pos rifampin	Recovered
14** ¹⁶	<i>M. chelonae</i>	Culture of PD effluent	Yes	Yes	ip amikacin, ip imipenem/cilastatin	Recovered
15 ¹⁶	<i>M. chelonae</i>	Culture of ES drainage	Yes	Yes	iv amikacin, iv imipenem/cilastatin => iv clarithromycin, iv levofloxacin	Recovered
16 ¹⁶	<i>M. chelonae</i>	Culture of ES drainage	Yes	Yes	iv vancomycin => iv amikacin, iv imipenem/cilastatin, iv clarithromycin, iv levofloxacin	Recovered
17 ¹⁷	<i>M. abscessus</i>	Culture of PD effluent + MALDI-TOF + WGS	Yes	Yes	iv ceftazidime, iv gentamicin => iv amikacin, iv meropenem, pos clarithromycin	Recovered
18 ¹⁸	<i>M. abscessus</i>	Culture of PD effluent and ES drainage	Yes	Yes	ip cefazolin, ip ceftazidime + iv amikacin, iv vancomycin => pos clarithromycin, pos clofazimine, iv amikacin	Recovered
19 ¹⁹	<i>M. avium</i>	Culture of PD effluent	Yes	Yes	ip vancomycin, ip ceftazidime => clarithromycin, ciprofloxacin, meropenem => pos clarithromycin, pos ethambutol, pos rifampin	Recovered
20 ²⁰	<i>M. fortuitum</i>	Culture of PD effluent	Yes	Yes (switch to HD for 8 months, then RT)	ip ceftazidime, ip cefazolin, ip vancomycin => iv imipenem, iv amikacin, pos moxifloxacin => pos trim/sulfo, iv amikacin, pos moxifloxacin => pos ciprofloxacin, pos moxifloxacin, => pos linezolid, pos clofazimine (6m)	Recovered
21 ²¹	<i>M. abscessus</i>	Culture of PD effluent + MALDI-TOF +PCR	Yes	Yes (switch to HD for 4 months, then RT)	pos cefcapene pivoxil, pos sulfamethoxazole/trimethoprim => iv cefazolin => iv cefotaxime => ip meropenem, iv vancomycin => iv linezolid, iv piperacillin/tazobactam => iv amikacin, iv imipenem/cilastatin sodium, pos clarithromycin => iv tigecycline, iv imipenem/cilastatin sodium (6m)	Recovered

22 ²²	<i>M. abscessus</i>	Culture of intraoperative peritoneal fluid	Yes	Yes (switch to HD for 8 months, then RT)	Ip ceftazidime, ip cefazolin => IP vancomycin, ip gentamicin => iv meropenem, iv vancomycin, iv fluconazole => exploratory laparoscopy along with abdominal washout	Recovered
23 ²³	<i>M. fortuitum</i>	Culture of PD effluent and ES drainage	Yes	Yes (switch to HD for 2 months, the PD catheter was replaced and PD was resumed)	pos cefcapene, iv gentamycin => pos norfloxacin => iv amikacin, iv imipenem/cilastatin, ip+iv ciprofloxacin => pos clarithromycin, pos norfloxacin (12m)	Recovered
24 ²⁴	<i>M. abscessus</i>	Culture of ES drainage	Yes	No	pos cefaclor=> iv cefazolin => iv amikacin (AMK), iv imipenem/cilastatin sodium (IPM/CS), pos clarithromycin (2m) – Debridement of the infected site	Recovered
25 ²⁵	<i>M. abscessus</i>	Culture of PD effluent	Yes	Yes	ip ceafazolin, ip ceftazidime => iv vancomycin, iv ceftazidime => iv imipemen, iv clarithromycin, iv amikacin, iv linezolid (2m) => pos clarithromycin, pos limezolid, pos moxifloxacin (5m) – abdominal washout and lavage	Recovered

NTM, nontuberculous *Mycobacteria*; PD, peritoneal dialysis; ip, intraperitoneal; pos, per os; iv, intravenous; NA, not available; CAPD, continuous ambulatory peritoneal dialysis; RT renal transplantation; HD, hemodialysis; ES, exit site; MALDI-TOF, matrix-assisted laser-desorption ionization time of- flight mass spectrometry; WGS, whole-genome sequencing, m, months;

*Patient 11 and 12 are the same at different age

**Patient 13 and 14 are the same at different age

Table 3. Data of isolates from 25 cases of peritoneal dialysis-related infections due to nontuberculous *Mycobacteria* and kind of induced infection

Isolates	Frequency Percent (%)	Kind of induced infection
<i>Mycobacterium abscessus</i>	7 (28)	3 peritonitis 2 ESI 2 peritonitis/ESI
<i>Mycobacterium fortuitum</i>	7 (28)	4 peritonitis 2 ESI 1 peritonitis/ESI
<i>Mycobacterium chelonae</i>	6 (24)	1 peritonitis 5 ESI
<i>Mycobacterium avium</i>	4 (16)	4 peritonitis
Group II Scotochromogenic M.	1 (4)	1 peritonitis
Total	25 (100)	13 peritonitis 9 ESI 3 peritonitis/ESI

ESI, exit-site infection